CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

Tomoyuki Otsuka1,2†, Sumiyuki Nishida1*†, Takayuki Shibahara1,3, Burcu Temizoz3,4,5, Masanari Hamaguchi1, Takayuki Shiroyama1, Keiko Kimura6, Kotaro Miyake1, Haruhiko Hirata1, Yumiko Mizuno1, Mayu Yagita1, Yusuke Manabe1, Etsushi Kuroda3,4,7, Yoshito Takeda1, Hiroshi Kida1,8, Ken J. Ishii3,4,5 and Atsushi Kumanogoh1,9,10

Abstract

Background: Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) (K3)—a novel synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a potential Th1-type immune response against cancer cells. We conducted a phase I study of CpG ODN (K3) in patients with lung cancer to assess its safety and patients’ immune responses.

Methods: The primary endpoint was the proportion of dose-limiting toxicities (DLTs) at each dose level. Secondary endpoints included safety profile, an immune response, including dynamic changes in immune cell and cytokine production, and progression-free survival (PFS). In a 3 + 3 dose-escalation design, the dosage levels for CpG ODN (K3) were 5 or 10 mg/body via subcutaneous injection and 0.2 mg/kg via intravenous administration on days 1, 8, 15, and 29.

Results: Nine patients (eight non-small-cell lung cancer; one small-cell lung cancer) were enrolled. We found no DLTs at any dose level and observed no serious treatment-related adverse events. The median observation period after registration was 55 days (range: 46–181 days). Serum IFN-α2 levels, but not inflammatory cytokines, increased in six patients after the third administration of CpG ODN (K3) (mean value: from 2.67 pg/mL to 3.61 pg/mL after 24 hours). Serum IFN-γ (mean value, from 9.07 pg/mL to 12.7 pg/mL after 24 hours) and CXCL10 levels (mean value, from 351 pg/mL to 676 pg/mL after 24 hours) also increased in eight patients after the third administration. During the treatment course, the percentage of T-bet-expressing CD8+ T cells gradually increased (mean, 49.8% at baseline and 59.1% at day 29, \( p = 0.0273 \)). Interestingly, both T-bet-expressing effector memory (mean, 52.7% at baseline and 63.7% at...
Background
Cancer immunotherapy involves the induction or enhancement of a pre-existing host anti-tumor immune response to eradicate cancer cells. Immune checkpoint inhibition has recently created a new paradigm to improve the survival of patients with cancer, including non-small-cell lung cancer (NSCLC) [1–3]. However, the long-term beneficial effects of immune checkpoint inhibitors (ICIs) may be limited to approximately 20% of patients with advanced NSCLC [4–7]. ICIs can activate pre-existing immune cells, but they do not induce or mobilize them into the tumor microenvironment. Hence, they must be combined with immune adjuvants to further improve the prognosis of cancer patients [8]. Immune adjuvants include pathogen-associated molecular patterns or damage-associated molecular patterns that can activate various pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), which are expressed on innate immune cells such as dendritic cells [9]. The activation of PRRs by immune adjuvants leads to the maturation of dendritic cells, which allows them to process antigens, present them to T cells, and produce type I IFNs and cytokines such as TNF-α and IL-12, resulting in the induction of antigen-specific immune responses [10].

Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) is a synthetic single-stranded DNA containing unmethylated CpG motifs commonly found in bacterial and viral genomes [11]. CpG ODNs are ligands for TLR9 that can activate both the TLR9-MyD88-IRF7 and TLR9-MyD88-NFκB signaling pathways to induce type I IFN and pro-inflammatory cytokine production by innate immune cells, leading to a Th1-type adaptive immune response [11]. Since Th1-type immune cells play a crucial role in anti-tumor immunity, CpG ODNs may contribute to the development of effective cancer immunotherapy.

CpG ODN (K3), a novel immune adjuvant developed by Ishii et al., has considerably high ability to stimulate human immune cells to proliferate and produce cytokines in vitro [12]. Recently, we conducted an investigator-initiated clinical trial of a CpG ODN (K3)-adjuvanted malaria vaccine in healthy volunteers. This vaccine was safe and tolerable and induced a more robust and substantially earlier immune response against the malaria antigen than the adjuvant-free vaccine did [13].

Herein, we present the results of our open-label, dose-escalation phase I trial to assess the safety profile and clinical and immune response of CpG ODN (K3) in patients with advanced lung cancer.

Methods
Study design
This study was an exploratory, prospective, dose-escalation phase I study on the safety and immunological effects of CpG ODN (K3) in patients with advanced lung cancer who had received standard platinum-based regimens. The study was approved by the institutional review board of Osaka University Hospital (reference number, 15507). Written informed consent was obtained from all patients before participation in the trial. The study was performed at Osaka University Hospital (Osaka, Japan) and registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN-000023276).

The primary endpoint was dose-limiting toxicities (DLTs) at each dose level. Secondary endpoints included progression-free survival (PFS), defined as the time from registration to documented disease progression or death from any cause; incidence of adverse events, assessed according to the Common Terminology Criteria for Adverse Events version 4.0; and immunological findings. Tumor response was based on investigator assessment according to the Response Evaluation Criteria in Solid Tumors version 1.1 [14].

Eligibility criteria were age between 20 and 79 years and histologically or cytologically confirmed NSCLC or small-cell lung cancer (SCLC). Eligible patients had undergone platinum-based chemotherapy alone or in combination with definitive radiation therapy. Additional inclusion criteria were no disease progression after treatments, an Eastern Cooperative Oncology
Group performance status of 0–1, completion of prior treatment within 4 months, and adequate organ function.

Treatment
Good manufacturing practice–grade CpG ODN (K3) (ATCG ACTC TCGA GCGT TCTC) synthesized by Gene Design (Ibaraki, Japan) was injected via subcutaneous (sc) or intravenous (iv) administration on days 1, 8, 15, and 29 (study treatment phase) and then every 4–6 weeks until a maximum of 6 months (compassionate use phase; Fig. 1a). Four basic doses of CpG ODN (K3) were scheduled: level 0, 5.0 mg/body sc; level 1, 10 mg/body sc; level 2, 0.2 mg/kg iv; and level 3, 0.6 mg/kg iv. Intrapatient dose escalation was not allowed during the DLT observation period.

Therapy was discontinued upon disease progression; severe adverse events, including grade 4 toxicities related to CpG ODN (K3); or request for withdrawal of consent. Concomitant treatment with bevacizumab maintenance therapy was allowed.

Follow-up
Patients were followed up for their general condition and vital signs daily for the first 15 days on an inpatient basis. Thereafter, administration and assessment were performed on an outpatient basis. Blood tests were performed at baseline and after every administration (blood cell counts were also obtained on days 2 and 16 after a protocol amendment; Fig. 1a). Urine tests were performed at baseline and on days 15 and 29. Computed tomography was performed every 8 weeks until disease progression.

Definition of DLTs
DLT was defined as the occurrence of any of the following, except for toxicities not related to CpG ODN (K3), from the first administration (day 1) to immediately after the third administration (day 15; Fig. 1a): (i) Grade 3 or 4 fever for 7 days or more; (ii) Grade 3 flu-like symptoms for 7 days or more; (iii) Grade 3 or 4 local skin reaction at administration sites; (iv) Grade 3 or 4 allergic reaction; (v) anaphylaxis; (vi) Grade 3 or 4 pneumonitis; (vii) Grade 3 or 4 neutropenia; (viii) Grade 3 or 4 thrombocytopenia; (ix) Grade 3 or 4 activated partial thromboplastin time.

Fig. 1 Schemas of treatment schedule (a) and CONSORT subject flow diagram (b)
prolongation; and (x) Grade 3 or greater non-hematological toxicity for 3 days or more, except for nausea or vomiting, anorexia, chills, hypotension, malaise or fatigue, and electrode abnormalities that were reversible with appropriate treatment.

Estimation of MTD
For dose level escalation, a modified Fibonacci dose-escalation method (3+3 design) was used. At least three patients were treated at each dose level. If no DLT was observed, the dose was escalated to the next level. If one instance of DLT was observed among the three initial patients, an additional three patients were treated at the same dose level, and dose escalation was performed when no further DLTs were observed. If two of these six patients developed DLT, the dose level was estimated as the MTD.

Immunological assays of peripheral blood cells and serum
For immune assessment, PBMCs and serum were collected before and 24 h after the first and third administration and before the fourth administration of CpG ODN (K3) during the study (Fig. 1a). PBMCs isolated from the blood samples were stored in liquid nitrogen until analysis. For the phenotyping of T cells by transcription factors, frozen PBMCs were defrosted with DNase I treatment and stained for the following surface markers: anti-human CD3-AF700 (clone: SK7), CD4-BV650 (clone: OKT4), CD8-BV510 (clone: SK1), CD45RA-FITC (clone: HI100), and CCR7-PE/Cy7 (clone: G043H7) antibodies and anti-human CD14-APC-Cy7 (clone: M5E2), CD19-APC-Cy7 (clone: HIB19), and CD56-APC-Cy7 (clone: HCD56) antibodies for dump gating (exclusion from the analysis) of monocytes, B cells, and NK cells, respectively, for 30 min. The cells were then permeabilized and fixed with the fixation buffer from the Foxp3/Transcription Factor Staining kit (eBioscience, USA) for 1 h. Next, they were washed with perm/wash buffer and stained for the intracellular proteins using anti-human Foxp3/APC (clone: PCH101) and T-bet-PE-Dazzle 594 (clone: 4B10) antibodies for 30 min. Data were acquired using a modified BD LSR II Fortessa (BD Biosciences, USA) and analyzed using FlowJo software. Human 48-plex Bioplex assay (Bio-Rad, USA) was performed to measure chemokine and cytokine levels in serum samples.

Statistical analysis
PFS after registration was estimated using the Kaplan–Meier method to assess the time to disease progression or death. The cut-off date for data collection was March 24, 2020. Non-parametric Wilcoxon signed-rank test was used to calculate \( p \) values for the changes in immune cells and the levels of chemokines and cytokines. All analyses were performed using JMP Pro software, version 15 (SAS Institute Inc., Cary, NC, USA). Differences were considered statistically significant at \( p < 0.05 \).

Results
Patient characteristics
Between February 2017 and January 2019, we screened ten patients at Osaka University Hospital and enrolled nine in this study (Fig. 1b). Because of the enforcement of a new law on clinical research in Japan, we could complete only three of the four planned dosing levels (levels 0–2). The study was terminated on March 31, 2019. Patient characteristics at baseline are summarized in Table 1. Of the nine patients, eight had NSCLC (four adenocarcinomas, three squamous carcinomas, and one mucoepidermoid carcinoma), and one had SCLC. One patient (#08) discontinued first-line pembrolizumab therapy and then received platinum-based chemotherapy as a second-line treatment. The median time from the last treatment to enrollment in this study was 62 days. The median observation period after registration was 55 days (range: 46–181 days).

Treatment course
Three patients each were treated at each dose level of CpG ODN (K3) (Table 1). One patient (#02) was concomitantly administered bevacizumab with CpG ODN (K3). None of the patients received any prophylactic medication for adverse events of CpG ODN (K3).

All patients except patient #01 completed four CpG ODN (K3) doses during the study treatment phase (Table 1). Patient #01 discontinued the study treatment after three doses of CpG ODN (K3) because of non-symptomatic exacerbation of pneumonitis, which was probably related to prior chemoradiation therapy (CRT). Four patients continued to receive CpG ODN (K3) in the compassionate use phase, and three of them completed the planned six-month treatment (Table 1).

DLT and MTD of CpG ODN (K3)
No DLTs occurred in any of the patients at any dose level of CpG ODN (K3). We could not determine the MTD of CpG ODN (K3) at the dose settings in this study and estimated it to be greater than 10 mg sc or 0.2 mg/kg iv.

Toxicity: treatment-related adverse events
Treatment-related adverse events (TrAEs) at each dose level of CpG ODN (K3) are summarized in Table 2. In total, 27 systemic adverse events were reported (Supplementary Table S1), of which 16 (59.3%) were determined to be TrAEs. All systemic TrAEs were of grade 1 or 2, were reversible without any treatment, and improved
| Dose level | Patient | Primary cancer | Age | Gender | PS Smoking history | Stage | Prior therapy | Response to prior therapy | Time from the completion of prior therapy, (days) | No. of doses of CpG ODN (K3), n (n)a | Response to CpG ODN (K3) | PFS, (days) |
|------------|---------|----------------|-----|--------|-------------------|-------|---------------|--------------------------|-------------------------------------------|---------------------------------|----------------------------|------------|
| 5 mg sc    | #01     | NSCLC          | 62  | F      | 0 Yes            | IIIA  | CRT           | PR                       | 45                                                       | 3 (0)                           | non-CR/non-PD                | 398        |
|            | #02     | NSCLC          | 59  | M      | 0 No             | IV    | Chemotherapy  | SD                       | 33                                                       | 4 (0)                           | PD                          | 50         |
|            | #03     | NSCLC          | 70  | M      | 1 Yes            | Recurrent | CRT         | CR                       | 109                                                      | 9 (5)                           | non-CR/non-PD                | 891b       |
| 10 mg sc   | #04     | NSCLC          | 72  | M      | 1 Yes            | Recurrent | Chemotherapy | PR                       | 88                                                       | 8 (4)                           | non-CR/non-PD                | 330c       |
|            | #05     | NSCLC          | 67  | F      | 0 No             | IV    | Chemotherapy  | PR                       | 71                                                       | 4 (0)                           | PD                          | 49         |
|            | #06     | SCLC           | 67  | M      | 0 Yes            | IV    | Chemotherapy  | PR                       | 43                                                       | 5 (1)                           | PD                          | 72         |
| 0.2 mg/kg iv| #07    | NSCLC          | 68  | M      | 1 Yes            | IV    | Chemotherapy  | SD                       | 97                                                       | 9 (5)                           | SD                          | 294        |
|            | #08     | NSCLC          | 72  | M      | 1 Yes            | IIIb  | Chemotherapy  | PR                       | 36                                                       | 4 (0)                           | SD                          | 410b       |
|            | #09     | NSCLC          | 77  | M      | 1 Yes            | IIIb  | Chemotherapy  | PR                       | 62                                                       | 4 (0)                           | SD                          | 402b       |

NOTE: a: The letter "n" refers to the total number of administrations of CpG ODN (K3) during the study (study treatment phase plus the compassionate use phase). The maximum number is 5. b: These patients remained in progression-free survival on the cutoff date. c: These survival data were censored at the last observation. d: This patient received an alternative anticancer therapy before radiological confirmation of disease progression. Survival data for this patient were censored at the beginning of the other treatment. Abbreviations: sc Subcutaneous injection, iv Intravenous administration, M Male, F Female, PS Performance status, NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, CRT Chemoradiotherapy, PR Partial remission, SD Stable disease, CR Complete remission, PD Progressive disease, PFS Progression-free survival.
after the next administration. No symptoms or signs such as fever of >38.0°C or lymphadenopathy, which were assumed to occur as immune reactions related to CpG ODN (K3), were observed. No physical signs or symptoms suggesting the induction of autoimmunity were observed. No apparent differences in the incidence of each TrAE were noted between the dose groups.

All patients of the sc groups except one (#02) exhibited mild local skin reactions at the injection sites within 48 h of the administration of CpG ODN (K3) (Table 2). There were no accompanying symptoms such as itching, and no treatment was required. No apparent differences in the severity of local skin reactions were noted between the two sc groups.

**Clinical effects of CpG ODN (K3)**
Six of the nine patients (66.7%) had stable disease or non-CR/non-PD for 6 months as the best overall response (Table 1). The median PFS was 398 days (range, 49–891; Table 1 and Supplementary Fig. S1). No apparent association was noted between the dose level of CpG ODN (K3) and clinical effects. Notably, three patients (#03, #08, and #09) remained stable for over 1 year after the last administration of CpG ODN (K3).

**Immune assessment 1: effects on peripheral blood**
We evaluated the effects of CpG ODN (K3) on peripheral blood cells such as lymphocytes, neutrophils, and monocytes. The lymphocyte counts decreased temporarily within 24 h of the administration of CpG ODN (K3) in all patients and returned to baseline by the next dosing schedule (Fig. 2a). In contrast, neutrophil counts appeared to increase temporarily within 24 h of the administration of CpG ODN (K3) (Fig. 2b), although no regular changes in monocyte counts were observed (Fig. 2c).

**Immune assessment 2: chemokine or cytokine production in response to CpG ODN (K3)**
We evaluated the changes in serum cytokine and chemokine levels. Their levels increased to varying degrees within 24 h of CpG administration (Supplementary Fig. S2). We mainly focused on the time courses of IFN-α2, TNF-α, IFN-γ, and CXCL10 in response to CpG ODN (K3) (Table 3). The relative changes in these cytokines and chemokines during the acute phase within 24 h of treatment were more prominent after the third injection than after the first injection.

Type I IFNs and inflammatory cytokines are the markers of innate immune activation by CpG ODN (K3) [11]. In six patients, the serum levels of IFN-α2 increased mildly after the third administration of CpG ODN (K3) [mean IFN-α2 level, 2.67–3.61 pg/mL; median relative change, 67.8% (range: −38.6 to 191.7%)], irrespective of the dose level or administration route (Fig. 3a and Table 3). In contrast, only a slight change in TNF-α levels

### Table 2 Treatment-related Adverse Events

| Adverse event                        | 5 mg sc (n = 3) | 10 mg sc (n = 3) | 0.2 mg/kg iv (n = 3) |
|--------------------------------------|----------------|-----------------|---------------------|
|                                      | Any Grade  | Grade ≥ 3      | Any Grade  | Grade ≥ 3      | Any Grade  | Grade ≥ 3      |
| White blood cell decreased           | 0          | 0               | 1          | 0               | 0          | 0               |
| Neutrophil count decreased           | 1          | 0               | 1          | 0               | 0          | 0               |
| Lymphocytes count decreased          | 1          | 0               | 1          | 0               | 0          | 0               |
| Platelet count decreased             | 0          | 0               | 1          | 0               | 1          | 0               |
| Eosinophil count increased           | 1          | 0               | 0          | 0               | 0          | 0               |
| ALT increased                        | 0          | 0               | 1          | 0               | 0          | 0               |
| ALP increased                        | 0          | 0               | 0          | 0               | 0          | 0               |
| Hypocalcemia                         | 0          | 0               | 1          | 0               | 0          | 0               |
| Hypoalbuminemia                      | 0          | 0               | 1          | 0               | 0          | 0               |
| Urinary protein                      | 0          | 0               | 1          | 0               | 0          | 0               |
| Hematuria                            | 0          | 0               | 0          | 0               | 1          | 0               |
| Pneumonitis                          | 1          | 0               | 0          | 0               | 0          | 0               |
| Maculopapular rash                   | 0          | 0               | 0          | 0               | 1          | 0               |

**Skin reactions at the local injection site**
Redness: 2, 0, 3, 0, NE, NE
Induration: 1, 0, 2, 0, NE, NE

NOTE: *Treatment-related adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Abbreviations: sc Subcutaneous injection, iv Intravenous administration, AST Aspartate aminotransferase, ALT Alanine aminotransferase, NE Not evaluated
was observed after the third CpG ODN (K3) dose in all patients [mean TNF-α level, 48.6–47.9 pg/mL; median relative change, 4.98% (range: −29.1 to 24.9%)] (Fig. 3b and Table 3). Very few biologically meaningful changes were noted in the levels of other inflammatory cytokines, including IL-1β, IL-6, and IL-12 (Supplementary Fig. S2), suggesting that CpG ODN (K3) predominantly elicited type I IFN responses rather than inflammatory cytokine responses.

Next, we assessed the markers for adaptive immune activation, such as IFN-γ for Th1 response, IL-4 for Th2 response, and IL-17 for Th17 response. Eight patients had mild increases in serum IFN-γ level after the third dose [mean IFN-γ level, 9.07–12.7 pg/mL; median relative change, 24.9% (range: −23.1 to 124.7%)] (Fig. 3c and Table 3). Five patients (#03, #05, #06, #07, and #09) had a mild-to-moderate increase in IFN-γ level in addition to a more than 50% relative increase in IFN-α2 (Table 3 and Fig. 3c). These results suggested that the increase in IFN-γ was related to the release of IFN-α2. However, the patients in the iv group had a weaker Th1 response than those in the sc groups. The mean relative changes in IFN-α2 in the iv and sc groups were 22.2% (range: 19.4–24.9%) and 76.4% (range: 23.9–124.7%), respectively. Unlike for IFN-γ, all patients showed minimal changes in serum IL-4 and IL-17 levels (Supplementary Fig. S2).

The serum levels of several chemokines, including CXCL10, CCL2, and CXCL9, increased temporarily within 24 h of CpG ODN (K3) administration (Fig. 3d and Supplementary Fig. S2). The serum level of CXCL10, also known as IFN-γ-induced protein 10, was increased in eight patients with relatively increased serum IFN-γ levels after the third dose [mean CXCL10 level, 351–676 pg/mL; median relative change, 97.6% (range: −30.9 to 471.1%)] (Fig. 3d and Table 3). These responses were also considerably marked in the sc groups, but not dose-dependent.

**Immune assessment 3: induction of adaptive cellular immunity in response to CpG ODN (K3)**

We evaluated the effect of CpG ODN (K3) on adaptive cellular immunity. Overall, no notable changes were observed in lymphocyte subsets of CD4- or CD8-positive CD3+ T cells and the percentages of their immune phenotypes (Supplementary Table S2).

First, we evaluated the functional characteristics of CD4+ T cells by analyzing T-bet and Foxp3 expression (Supplementary Fig. S3a). The percentages of T-bet+ and Foxp3+ CD4+ T cells were approximately 4–5% of the CD4+ T cells in PBMCs collected from two healthy subjects as controls (Supplementary Fig. S3b). Figure 4 (a–c) presents the classifications of patients into three groups based on T-bet or Foxp3 expression at baseline. In group 1, two patients (#03 and #09) exhibited a gradual increase in T-bet-expressing CD4+ T cells during the treatment course (24.7 and 13.7%, respectively, at baseline to 45.3}
and 18.0% at day 29) (Fig. 4a). In contrast, in the other two groups, T-bet or Foxp3 expression in the CD4+ T cells changed minimally or fluctuated slightly during the treatment course (Fig. 4b-c). Immunophenotypically, especially in group 1, T-bet-expressing effector memory (EM) CD4+ T cells increased (Fig. 4d), whereas Foxp3-expressing EM CD4+ T cells remained almost unchanged during the treatment course (Supplementary Fig. S4).

Next, we evaluated the functional characteristics of CD8+ T cells by analyzing T-bet expression (Supplementary Fig. S3a). The percentage of T-bet+ CD8+ T cells was approximately 30% of the CD8+ T cells in the PBMCs collected from the two healthy subjects (Supplementary Fig. S3b). At baseline, all patients exhibited higher percentage of T-bet-expressing CD8+ T cells than those in the healthy subjects (Fig. 4e). During the treatment course, the percentage gradually increased (mean [range]: 49.8% [32.5–76.2] at baseline and 59.1% [41.9–84.9] at day 29, p = 0.0039; Fig. 4f).

Table 3 Summary of cytokines and chemokines released or produced in response to CpG ODN (K3)

| Dose Level | Pt. | 1st administration | 3rd administration |
|------------|-----|---------------------|---------------------|
|            |     | IFN-α2 | TNF-α | IFN-γ | CXCL10 | IFN-α2 | TNF-α | IFN-γ | CXCL10 |
| 5 mg sc    |      |         |       |       |        |        |       |       |        |        |
| #01        | ▲   | 24.8    | ▲13.7 | ▲26.3 | 183.9  | ▲31.4  | 24.9  | 57.2  | 471.1  |
| #02        | 8.3  | ▲1.29  | ▲13.9 | ▲3.3  | 18.5   | ▲15.9  | 23.9  | 161.0 |
| #03        | 100.0 | ▲12.2 | 24.7  | 160.5 | 151.7  | ▲20.9  | 95.6  | 119.5 |
| #04        | 62.8 | 11.2    | 21.5  | ▲8.7  | ▲38.6  | 5.0    | 8.8   | 35.54 |
| #05        | ▲59.4 | ▲22.7 | ▲36.3 | ▲35.5 | 67.8   | 17.0   | 61.5  | 97.6   |
| #06        | ▲26.6 | ▲10.8 | 52.9  | 119.6 | 131.0  | 11.1   | 124.7 | 184.3 |
| 10 mg sc   |      |         |       |       |        |        |       |       |        |        |
| #07        | ▲48.2 | ▲15.3 | ▲11.7 | ▲37.7 | 100.0  | ▲5.0   | 24.9  | 2.59  |
| #08        | 485.1 | 32.3   | ▲8.8 | 72.5  | ▲38.4  | ▲29.1  | ▲23.7 | ▲30.9 |
| #09        | ▲25.8 | ▲26.6 | ▲11.7 | ▲15.6 | 191.7  | 10.0   | 19.4  | 53.2  |

* Comparison of IFN-α2, TNF-α, IFN-γ, or CXCL10 concentrations before and 24 h after the administration of CpG ODN (K3). Each value represents the relative change between before and 24 h after the administration of CpG ODN (K3), which was defined (post level – pre level)/pre level (%). ▲ italic represents a negative value

Abbreviations: sc Subcutaneous injection, iv Intravenous administration

Within 24 h of CpG ODN (K3) administration, his lymphocyte level temporally decreased (Fig. 2a) and serum IFN-α2, IFN-γ, and CXCL10 levels temporally increased (Fig. 5c). The T-bet expression in CD4+ T cells was approximately twice that of any other patients before the administration of CpG ODN (K3). During the treatment course, T-bet expression increased, whereas Foxp3 expression remained low (Fig. 5d). Notably, T-bet expression in EM CD4+ T cells increased after repeated CpG ODN (K3) administration and remained high for six months (Fig. 5e). T-bet expression also increased in CD8+ T cells (Fig. 5e). In CD8+ T cells, the percentage of TEMRA cells increased, whereas that of EM cells decreased, but both immune phenotypes showed a gradual increase in T-bet expression during the treatment course (Fig. 5e). The Th1-type cellular immune response sustained by CpG ODN (K3) possibly contributed to disease stabilization and led to better clinical results.

**Discussion**

We conducted the first clinical study of CpG ODN (K3) in cancer patients. CpG ODN (K3) is expected to activate dendritic cells, leading to the initiation or enhancement of cancer immunity [15].

We observed no DLTs of CpG ODN (K3) at any dose level and could not determine the MTD of CpG ODN (K3) in our clinical setting. All systemic TrAEs were mild-to-moderate sporadic organ manifestations. No apparent differences in the profiles of systemic TrAEs...
Fig. 3 Dynamic changes in the levels of IFN-α2 (a), TNF-α (b), IFN-γ (c), and CXCL10 (d) in individual cases (#01, #02, and #03 in the 5 mg sc cohort; #04, #05, and #06 in the 10 mg sc cohort; and #07, #08, and #09 in the 0.2 mg/kg iv cohort). Peripheral blood samples were collected before (pre) the first and third administration and 24 h after the first and third administration of CpG ODN (K3). Horizontal bars represent median values.
were noted among the doses or routes of administration of CpG ODN (K3). No novel toxicities related to CpG ODNs, including autoimmune diseases, were found, and the toxicity profile of CpG ODN (K3) was similar to those of other CpG ODNs [16–25]. These results suggested that both sc and iv administration of CpG ODN (K3) were safe and well-tolerated. Several groups have shown that CpG ODNs cause TrAEs such as flu-like symptoms, lymphadenopathy, or coagulation abnormalities [16–25]. However, these adverse events were not noted in our patients. These results suggested that either the immunostimulatory and immunomodulatory functions of CpG ODN (K3) might differ from those of other CpG ODNs or the dose of CpG ODN (K3) used in this study could have failed to trigger these events.

One of the two patients treated with CRT as a prior treatment developed grade 1 interstitial pneumonitis after the third dose of CpG ODN (K3). This condition was probably a late effect of the prior radiation therapy. However, the immunity activated by CpG ODN (K3) might have exacerbated the condition. The other patient did not develop interstitial pneumonitis during the study and follow-up. Further clinical investigation is required.

As reported previously [16], we observed a transient decrease in lymphocytes. Although the detailed mechanism is unknown, this phenomenon could be related to the transient increase in chemokines after CpG ODN administration. In our study, serum CXCL-10 level increased transiently in response to CpG ODN (K3). CXCL-10 is a critical chemokine for effector T cell recruitment [16, 23, 25, 26]. The combination therapy of CpG ODN (K3) and ICIs might be a promising strategy for overcoming resistance to ICIs by facilitating the recruitment of effector T cells to the tumor site [26, 27].

Both sc and iv administration of CpG ODN (K3) led to the moderate production of IFN-α2 but no or slight increase in the serum levels of inflammatory cytokines, including TNF-α and IL-12. These results suggested that CpG ODN (K3) could predominantly activate the TLR9-IRF7 signaling pathway in lung cancer patients. Type I IFNs produced by plasmacytoid dendritic cells enhance the cytotoxic activities of natural killer cells and CD8+ CTLs and promote the differentiation of CD4+ helper T cells, resulting in enhanced tumor-specific immune responses. The lack of serious TrAEs in this study could be because CpG ODN (K3) did not strongly induce inflammatory cytokines.

These immune responses were more remarkable after the third dose of CpG ODN (K3) than after the first dose. Studies using both mouse and primate models have shown that the adjuvant effects of CpG ODN (K3) were higher after multiple immunizations than after a single dose [28, 29]. Thus, we recommend a weekly schedule as the initial administration of CpG ODN (K3) for cancer immunotherapy to induce an early immune activation for targeting cancer cells.

In patients with greater T-bet expression than Foxp3 in CD4+ T cells (group 1), CD4+ T cells maintained or increased T-bet expression and immunophenotypically differentiated into EM-type T cells. Interestingly, in these patients, IFN-α2 increased notably in response to CpG ODN (K3) compared to that in other patients. These results suggested that CpG ODN (K3) could activate the Th1-type immune response in lung cancer patients. Thus, the frequency of CD4+ T cells with predominant T-bet expression may be a potential predictive biomarker for CpG ODN-based cancer immunotherapy.

T-bet expression represents the differentiation of cytotoxic CD8+ T cells because these cells require T-bet for IFN-γ and granzyme B production [30, 31]. The increase in IFN-γ could reflect the enhancement of cytotoxic activity by the differentiation into the effector phenotype. T cells are not directly responsive to CpG ODNs because of the lack of TLR9 expression. We presume that dendritic cells activated by CpG ODN (K3) stimulate CD8+ T cells through the interaction between the HLA/antigen peptide complex and T cell receptor, and then CD8+ T cells differentiate into effectors and exert a CTL response. These observations also suggest that CpG ODN (K3) induced a Th1-type immune response and enhanced cytotoxic activity in lung cancer patients.

This study designed two routes: sc and iv routes. The sc administration of CpG ODNs, which has been utilized by several clinical studies, activates localized dendritic cells at injection sites. Conversely, the iv administration of CpG ODNs is expected to systemically activate innate immunity, particularly immune cells in the tumor microenvironment, but the safety of this administration route...
Fig. 4 (See legend on previous page.)
has not been thoroughly evaluated. A preclinical study with a primate model showed that repeated administration of CpG ODN (K3) via the iv route was safe and increased serum levels of IFN-α2 [32]. In this study, we showed that 0.2mg/kg by 30min iv infusion of CpG ODN (K3) was as safe as the sc route and elicited Th1-type immune responses. However, these responses were comparable or slightly inferior to those via the sc route with regard to the production of systemic cytokines such
as IFN-α2 and IFN-γ. This could be because of the rapid metabolic decomposition of CpG ODN in the blood [17]. Further investigation is necessary to determine the recommended dose and duration of iv administration of CpG ODN (K3).

This study has at least two limitations. First, we could not perform dose escalation in the iv cohort. The dose-dependent safety and immune effects of the iv administration and the MTD of CpG ODN (K3) remain unknown. Second, the number of patients was too small to allow the statistical assessment of the association between clinical outcome and immune response.

We recently reported the bioactivity of K3-SPG, a nanoparticulate CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan [33]. This modification improves the drug delivery of CpG ODN (K3) to dendritic cells, thereby increasing type 1 IFN production. In a primate study, K3-SPG monotherapy induced a potent antigen-specific memory CTL response [32]. To conduct a clinical study of K3-SPG, we needed to confirm the clinical safety and potency of CpG ODN (K3) in cancer patients.

In the near future, we will plan to conduct the clinical trial of CpG ODN (K3) in combination with other cancer immunotherapies, including ICIs and cancer vaccines. These combinations are expected to additively enhance the anti-tumor immune response against lung cancer and other solid cancers. On the other hand, the combination immunotherapies may also emerge immune-related adverse events unexpected. We will also conduct the first clinical study to evaluate the safety and efficacy of K3-SPG in patients with solid cancers and then design a combination therapy with other cancer immunotherapies.

Conclusions

CpG ODN (K3) is safe as an immune adjuvant in patients with advanced lung cancer. The administration of CpG ODN (K3) via either sc or iv route activated innate immunity, leading to the elicitation of Th1-type adaptive immune responses and enhancement of cytotoxic activity. Further clinical studies are needed to determine whether cancer patients have beneficial clinical outcomes with CpG ODN (K3) alone or in combination with other agents, especially ICIs.

Abbreviations

CpG ODN: Cytosine-phosphate-guanine oligodeoxynucleotide; DLT: Dose-limiting toxicity; EM: Effector memory; IC: Immune checkpoint inhibitor; iv: Intravenous; MTD: Maximum tolerated dose; NSCLC: Non-small-cell lung cancer; PFS: Progression-free survival; PRR: Pattern-recognition receptor; sc: Subcutaneous; SCLC: Small-cell lung cancer; TEMRA: Terminally differentiated cancer; TGF: Transforming growth factor; TLR: Toll-like receptor; TRAE: Treatment-related adverse event; UMIN: University Hospital Medical Information Network.

Additional file 1: Supplementary Table S1. Adverse Events. Supplementary Table S2. Immune phenotypes of CD4+ and CD8+ T cells.

Additional file 2: Supplementary Fig. S1. Kaplan–Meier curves for progression-free survival (PFS). Supplementary Fig. S2. Analysis of chemokines and cytokines. Supplementary Fig. S3. Gating strategy for immune phenotyping and functional characteristics of T cells. Supplementary Fig. S4. Foxp3 expression in effector memory of CD4+ T cells in individual cases.

Acknowledgments

We thank all the patients who participated in this study, their supporting families, referring physicians, and the supporting medical staffs at Osaka University Hospital. We also thank Atsue Watanabe, Miho Tarui, and Sachiko Kawai (Osaka University) for their professional and technical supports, Takuya Yamamoto, Natsuko Kishishita, Shingo Kobari (National Institutes of Biomedical Innovation, Health and Nutrition), and Tomomi Yamada (Osaka University) for their professional advice about the planning of this study.

Authors' contributions

TO and SN contributed to the design of the study. TO, SN, TS1, MH, TS2, KM, HH, YM1, MY, YM2, YT, and HK contributed to patient recruitment, treatment, and clinical data collection. KK contributed to clinical data collection and quality control of data. TO, SN, TS1, BT and EK contributed to immune response analysis. TO, SN, TS1, BT, TS2, KI, and AK interpreted the data. TO and SN performed the statistical analyses. TO and SN wrote the manuscript. All authors contributed to draft revisions and approved the final manuscript.

Funding

This work was supported by Japan Agency for Medical Research and Development (AMED) under Grant number 20ak0101066h0004; the Japanese Ministries of Education, Culture, Sports, Science and Technology, and of Health, Labor and Welfare (USPS KAKENHI) under Grant number JP19K07729; and the Japan Research Foundation for Clinical Pharmacology. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

The study was approved by the institutional review board of Osaka University Hospital (reference number, 15507) and was registered with the UMIN Clinical Trials Registry (registration no. UMIN-00023276). The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to undergoing any study-related procedure.

Consent for publication

Written informed consent for publication, including images and clinical data, was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan. 2. Department of Medical Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka 541-8567, Japan. 3. Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. 4. Laboratory of Vaccine Science, Immunology Frontier Research Center, Osaka University.
References

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2434–2454. https://doi.org/10.1056/nejmoa1200690.

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/nejmoa1507643.

3. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. https://doi.org/10.1056/nejmoa1606774.

4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small-cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5:1411–20. https://doi.org/10.1001/jamaoncol.2019.2187.

5. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004–12. https://doi.org/10.1200/jco.2014.58.3708.

6. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36:1675–84. https://doi.org/10.1200/jco.2017.77.0412.

7. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. MGN1703, an immune-modulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol. 2015;94:31–44. https://doi.org/10.1016/j.critrevonc.2014.12.002.

8. Kallies A, Good-Jacobson KL. Transcription factor T-bet orchestrates lineage development and function in the immune system. Trends Immunol. 2013;34:337–46. https://doi.org/10.1016/j.it.2013.07.003.

9. Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. Hum Vaccin Immunother. 2013;9:283–90. https://doi.org/10.4161/hv.22950.

10. Kawai T, Akira S. The role of pattern-recognition receptors in innate and adaptive immunity. Nat Rev Immunol. 2011;11:573–84. https://doi.org/10.1038/nri.1863.

11. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–84. https://doi.org/10.1038/nrd2059.

12. Krieg AM, Oguma T, Packham M, Gurtner GC, Gruchy JA, Rennick D, et al. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001;166:2372–7. https://doi.org/10.4049/jimmunol.166.4.2372.

13. Ezoe S, Palpacenc NMQ, Tetsunai K, Yamamoto K, Okada K, Taira M, et al. First-in-human randomised trial and follow-up study of plasmidodium falciparum blood-stage malaria vaccine BK-S36 with CpG-ODN(NK3). Vaccine. 2020;38:2746–57. https://doi.org/10.1016/j.vaccine.2020.09.056.

14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejc.2008.10.026.

15. Chen DS, Hellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. https://doi.org/10.1016/j.immuni.2013.07.012.

16. Krieg AM, Eier SM, Wittig B, Arnold D, Riera-Kronenschild J, Nitsche D, Kroening H, et al. Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–24. https://doi.org/10.1007/s00432-014-1682-7.

17. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–24. https://doi.org/10.1007/s00432-014-1682-7.

18. Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Becker HJ, Schmidt M, Hacker U, et al. Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. Eur J Cancer. 2015;51:146–56. https://doi.org/10.1016/j.ejca.2014.11.002.

19. Ursu R, Tollibert S, Banissi C, Vicart E, Ballon O, Le Rhun E, et al. Immuno-therapy with CpG-ODN in nonpeplinic meningiomas: a phase I trial. Cancer Sci. 2015;106:1212–8. https://doi.org/10.1111/cas.12724.

20. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711–23. https://doi.org/10.1016/j.ccell.2017.04.003.

21. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139–47. https://doi.org/10.1038/nrc.2017.117.

22. Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, et al. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AGH malaria vaccine in nonhuman primate models. Hum Vaccin Immunother. 2013;9:283–90. https://doi.org/10.4161/hv.22950.

23. Ito S, Hirose S, Kavakita T, Salt O, Quan YS, Kamiyama F, et al. Characteristic of K3 (CpG-ODN) as a transcutaneous vaccine formulation adjuvant. Pharmaceutics. 2020;12:267. https://doi.org/10.3390/pharmaceutics12030267.

24. Lazarevic V, Glimerch LH, Lord GM. B-cell: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13:777–89. https://doi.org/10.1038/nri3536.
32. Masuta Y, Yamamoto T, Natsume-Kitatani Y, Kanuma T, Moriishi E, Kobiya-
    ama K, et al. An antigen-free, plasmacytoid dendritic cell-targeting immu-
    notherapy to bolster memory CD8(+) T cells in nonhuman primates. J
    Immunol. 2018;200:2067–75. https://doi.org/10.4049/jimmunol.1701183.

33. Kobiyama K, Aoshi T, Narita H, Kuroda E, Hayashi M, Tetsutani K, et al.
    Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanopar-
    ticulate TLR9 agonist. Proc Natl Acad Sci U S A. 2014;111:3086–91. https://
    doi.org/10.1073/pnas.1319268111.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.